We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for burosumab (Kyowa Kirin Australia Pty Ltd)
Active ingredients
burosumab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
solution for injection
Indication
For the treatment of tumour-induced osteomalacia (TIO)
Therapeutic area
Musculoskeletal